市值不到80亿元的创新药企，股价突然暴跌，成A股跌幅最大个股

Group 1 - The core viewpoint of the news is that Frontier Biotech has entered into a significant licensing agreement with GlaxoSmithKline (GSK) for two small RNA products, despite experiencing a sharp decline in stock price shortly after the announcement [1][2] - The licensing agreement includes an upfront payment of $40 million and potential milestone payments totaling up to $950 million based on successful development and commercialization, along with tiered royalties on global net sales [1] - Following the announcement, Frontier Biotech's stock initially rose by 9.29% but subsequently fell by 15.59%, erasing the previous day's gains [2] Group 2 - Frontier Biotech has products that have achieved commercial sales, but the company is still operating at a loss [3] - The company projects a revenue of approximately 140 million to 145 million yuan for the fiscal year 2025, representing a year-on-year increase of 8.13% to 11.99% [3] - The expected net loss attributable to shareholders for 2025 is estimated to be between 255 million to 290 million yuan [3]